<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt; color: black"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: bold 10pt/18pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">CURRENT REPORT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>Date of Report (Date of earliest event
reported): January 31, 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ENTREMED, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact Name of Registrant as Specified in its
Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="text-align: center; vertical-align: top">
    <TD STYLE="width: 25%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-decoration: none"><U>DELAWARE<BR>
    </U>(State or other jurisdiction&nbsp; of incorporation or organization)</TD>
    <TD STYLE="width: 25%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><U>0-20713</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Commission File Number)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD STYLE="width: 25%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>58-1959440<BR>
</U>(IRS Employer Identification No.)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>9640 Medical Center Drive</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Rockville, Maryland</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>20850</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">____________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">(Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(240) 864-2600</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">_____________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">(Registrant&rsquo;s telephone number,
including area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Not Applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT>
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT>
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT>
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT>
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 1.01.&nbsp;&nbsp;Entry Into a Material Definitive Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As previously reported in its Current Report
on Form 8-K on September 10, 2010, EntreMed, Inc. (the &ldquo;Company&rdquo;) and Selected Value Therapeutics I, LLC (&ldquo;SVT&rdquo;)
entered into an agreement whereby the Company granted SVT an option to acquire certain license, development and commercialization
rights for ENMD-2076, the Company&rsquo;s lead compound, in China and certain of its territories (as amended, the &ldquo;China
Rights Agreement&rdquo;).&nbsp;&nbsp;&nbsp;On June 7, 2011, as previously announced, SVT exercised its right under the China Rights
Agreement to acquire such license to develop and commercialize ENMD-2076 and the parties commenced negotiations regarding a definitive
license agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On December 31, 2011, as previously announced,
the parties mutually agreed to extend the termination date from December 31, 2011 to January 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On<B> </B>February 1, 2012, the parties mutually
agreed to amend the China Rights Agreement to extend the termination date from January 31, 2012 to March 31, 2012 to permit the
parties to continue negotiating the terms and conditions of the license agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 1.02 Termination of a Material Definitive Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On January 31, 2012, the Company terminated
the Standby Equity Distribution Agreement dated as of June 28, 2011 (the &ldquo;SEDA&rdquo;) by and between the Company and YA
Global Master SPV Ltd (&ldquo;YA Global&rdquo;), an affiliate of Yorkville Advisors. The Company issued and sold $1.1 million of
shares of common stock under the SEDA prior to its termination. There were no penalties or fees paid in connection with the Company&rsquo;s
termination of the SEDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The SEDA was terminated in connection with the
closing of the Transaction (defined below).</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0"><B>Item 3.01 <FONT STYLE="color: black">Notice of Delisting
or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.</FONT></B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As previously reported in its Current
Report on Form 8-K filed on November 28, 2011, the Company received a letter from the Listing Qualifications Staff (the
&ldquo;Staff&rdquo;) of the Nasdaq Stock Market (&ldquo;Nasdaq&rdquo;), notifying the Company that it failed to comply with Nasdaq
Listing Rule 5550(b)(1), which requires the Company to maintain a minimum of $2.5 million in stockholders&rsquo; equity for continued
listing on the Nasdaq Capital Market if it does not otherwise meet the other requirements under the Nasdaq Capital Market continued
listing rules.&nbsp;&nbsp;Nasdaq granted the Company until January 6, 2012 to submit a plan to regain compliance with the continued
listing rule. The Company submitted a plan of compliance on January 6, 2012.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On February 3, 2012, the Company received
a letter from Nasdaq that it had accepted the Company&rsquo;s plan of compliance and, pursuant to such plan, has granted the Company
an extension until May 21, 2012 to evidence compliance with the Nasdaq continued listing rules. If the Company fails to evidence
compliance with the continued listing rules upon the filing of its periodic report for the quarter ending June 30, 2012, the Company
may be subject to delisting, at which time the Company may appeal the Nasdaq Staff&rsquo;s determination to a Nasdaq Hearings Panel.</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0"><B>Item 5.02. Departure of Directors or Principal Officers;
Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">(b)&#9;<I>Resignation of Directors</I></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On February 2, 2012, Michael M. Tarnow resigned
from the Board of Directors of the Company (the &ldquo;Board&rdquo;) and as Executive Chairman, effective immediately. Mr. Tarnow&rsquo;s
resignation from the Board did not involve any disagreement with the Company.</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On February 2, 2012, Donald S. Brooks
resigned from the Board of the Company and the Company&rsquo;s Audit, Compensation and Nominating and Corporate Governance Committees,
effective immediately. Mr. Brooks&rsquo; resignation from the Board or committees did not involve any disagreement with the Company.</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Messrs. Tarnow and Brooks voluntarily
resigned to facilitate the election of directors in connection with the Transaction as described below.</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">(d)&#9;<I>Election of Directors</I></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On February 2, 2012, the Board elected Dr. Wei-Wu
He as a director, effective immediately, with a term expiring at the annual meeting of stockholders to be held in 2012. At the
time of his election, the Board did not appoint Dr. He to any of its standing committees.</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On February 2, 2012, the Board also elected
Dr. Tak W. Mak as a director, effective immediately with a term expiring at the annual meeting of stockholders in 2013. At the
time of his election, the Board did not appoint Dr. Mak to any of its standing committees.</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The election of each of Dr. He and Dr. Mak were
made in accordance with the terms of the Convertible Note and Warrant Purchase Agreement, dated as of January 20, 2012, by and
among the Company and the parties thereto (the &ldquo;Purchase Agreement&rdquo;), executed in connection with the issuance and
sale of an aggregate of up to $10 million of notes (the &ldquo;Transaction&rdquo;). The Purchase Agreement provides that each of<FONT STYLE="color: black">
IDG-Accel China Growth Fund II L.P. (&ldquo;IDG&rdquo;) and Emerging Technology Partners, LLC (&ldquo;ETP&rdquo;)</FONT> collectively
have the right to designate up to two nominees to the Board. Dr. He and Dr. Mak were designated by ETP.</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Each of Dr. He and Dr. Mak will be compensated
consistent with the current compensation program for non-employee directors and did not enter into any compensation arrangements
at the time of their election.</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">A copy of the Company&rsquo;s press release
issued on February 6, 2012 regarding the election of Dr. He and Dr. Mak is filed as Exhibit 99.1 to this Form 8-K and is hereby
incorporated herein by reference.</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0"><B>Item 8.01. Other Information.</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In connection with the Transaction, Celgene
Corporation, the sole holder of the Company&rsquo;s outstanding Series A Convertible Preferred Stock (&ldquo;Series A Preferred&rdquo;),
agreed to vote in favor of the Transaction at the Company&rsquo;s 2012 stockholder meeting and, upon the approval of the Transaction
at such stockholder meeting, to (i) convert all outstanding shares of its Series A Preferred into common stock; (ii) waive all
accrued dividends on the Series A Preferred, and (iii) terminate all governance rights associated with the Series A Preferred.</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">A copy of the Company&rsquo;s press release
issued on February 6, 2012 regarding the consummation of the Transaction is filed as Exhibit 99.2 to this Form 8-K and is hereby
incorporated herein by reference.</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0"><B>Item 9.01. Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">(d) <I>Exhibits</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">99.1 &#9;Press Release issued by dated February 6, 2012.</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">99.2&#9;Press Release issued by dated February 6, 2012.</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;<FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/18pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 0">&nbsp;</P>


<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">ENTREMED, INC.</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%">By:&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 46%">/s/  Cynthia W. Hu</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: #000000 1px solid">Name: Cynthia W. Hu<BR>Title: &nbsp;&nbsp;COO, General Counsel &amp; Secretary</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;Date:
February 6, 2012</P>

<P STYLE="font: 10pt/18pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Exhibit Index</B></P>

<P STYLE="font: 10pt/18pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">99.1 &#9;Press Release issued by dated February 6, 2012.</P>

<P STYLE="font: 10pt/18pt Times New Roman, Times, Serif; margin: 0">99.2&#9;Press Release issued by dated February 6, 2012.</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v301436_8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 22848}]
{"company-data": {"conformed-name": "ENTREMED INC", "cik": "0000895051", "assigned-sic": "2836", "irs-number": "581959440", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-20713", "film-number": "12574297"}, "business-address": {"street1": "9640 MEDICAL CNTR DR", "street2": "STE 200", "city": "ROCKVILLE", "state": "MD", "zip": "20850", "phone": "3012179858"}, "mail-address": {"street1": "9640 MEDICAL CNTR SR", "street2": "STE 200", "city": "ROCKVILLE", "state": "MD", "zip": "20850"}}
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): January 31, 2012
ENTREMED, INC.
(Exact Name of Registrant as Specified in its
Charter)
DELAWARE
(State or other jurisdiction  of incorporation or organization)
0-20713
(Commission File Number)
58-1959440
(IRS Employer Identification No.)
9640 Medical Center Drive
Rockville, Maryland
______________________
(Address of principal executive offices)
20850
____________________
(Zip Code)
(240) 864-2600
_____________________
(Registrant's telephone number,
including area code)
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
£
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
£
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
£
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
£
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Item 1.01.  Entry Into a Material Definitive Agreement.
As previously reported in its Current Report
on Form 8-K on September 10, 2010, EntreMed, Inc. (the "Company") and Selected Value Therapeutics I, LLC ("SVT")
entered into an agreement whereby the Company granted SVT an option to acquire certain license, development and commercialization
rights for ENMD-2076, the Company's lead compound, in China and certain of its territories (as amended, the "China
Rights Agreement").   On June 7, 2011, as previously announced, SVT exercised its right under the China Rights
Agreement to acquire such license to develop and commercialize ENMD-2076 and the parties commenced negotiations regarding a definitive
license agreement.
On December 31, 2011, as previously announced,
the parties mutually agreed to extend the termination date from December 31, 2011 to January 31, 2012.
On
February 1, 2012, the parties mutually
agreed to amend the China Rights Agreement to extend the termination date from January 31, 2012 to March 31, 2012 to permit the
parties to continue negotiating the terms and conditions of the license agreement.
Item 1.02 Termination of a Material Definitive Agreement.
On January 31, 2012, the Company terminated
the Standby Equity Distribution Agreement dated as of June 28, 2011 (the "SEDA") by and between the Company and YA
Global Master SPV Ltd ("YA Global"), an affiliate of Yorkville Advisors. The Company issued and sold $1.1 million of
shares of common stock under the SEDA prior to its termination. There were no penalties or fees paid in connection with the Company's
termination of the SEDA.
The SEDA was terminated in connection with the
closing of the Transaction (defined below).
Item 3.01
Notice of Delisting
or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
As previously reported in its Current
Report on Form 8-K filed on November 28, 2011, the Company received a letter from the Listing Qualifications Staff (the
"Staff") of the Nasdaq Stock Market ("Nasdaq"), notifying the Company that it failed to comply with Nasdaq
Listing Rule 5550(b)(1), which requires the Company to maintain a minimum of $2.5 million in stockholders' equity for continued
listing on the Nasdaq Capital Market if it does not otherwise meet the other requirements under the Nasdaq Capital Market continued
listing rules.  Nasdaq granted the Company until January 6, 2012 to submit a plan to regain compliance with the continued
listing rule. The Company submitted a plan of compliance on January 6, 2012.
On February 3, 2012, the Company received
a letter from Nasdaq that it had accepted the Company's plan of compliance and, pursuant to such plan, has granted the Company
an extension until May 21, 2012 to evidence compliance with the Nasdaq continued listing rules. If the Company fails to evidence
compliance with the continued listing rules upon the filing of its periodic report for the quarter ending June 30, 2012, the Company
may be subject to delisting, at which time the Company may appeal the Nasdaq Staff's determination to a Nasdaq Hearings Panel.
Item 5.02. Departure of Directors or Principal Officers;
Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.
(b)
Resignation of Directors
On February 2, 2012, Michael M. Tarnow resigned
from the Board of Directors of the Company (the "Board") and as Executive Chairman, effective immediately. Mr. Tarnow's
resignation from the Board did not involve any disagreement with the Company.
On February 2, 2012, Donald S. Brooks
resigned from the Board of the Company and the Company's Audit, Compensation and Nominating and Corporate Governance Committees,
effective immediately. Mr. Brooks' resignation from the Board or committees did not involve any disagreement with the Company.
Messrs. Tarnow and Brooks voluntarily
resigned to facilitate the election of directors in connection with the Transaction as described below.
2
(d)
Election of Directors
On February 2, 2012, the Board elected Dr. Wei-Wu
He as a director, effective immediately, with a term expiring at the annual meeting of stockholders to be held in 2012. At the
time of his election, the Board did not appoint Dr. He to any of its standing committees.
On February 2, 2012, the Board also elected
Dr. Tak W. Mak as a director, effective immediately with a term expiring at the annual meeting of stockholders in 2013. At the
time of his election, the Board did not appoint Dr. Mak to any of its standing committees.
The election of each of Dr. He and Dr. Mak were
made in accordance with the terms of the Convertible Note and Warrant Purchase Agreement, dated as of January 20, 2012, by and
among the Company and the parties thereto (the "Purchase Agreement"), executed in connection with the issuance and
sale of an aggregate of up to $10 million of notes (the "Transaction"). The Purchase Agreement provides that each of
IDG-Accel China Growth Fund II L.P. ("IDG") and Emerging Technology Partners, LLC ("ETP")
collectively
have the right to designate up to two nominees to the Board. Dr. He and Dr. Mak were designated by ETP.
Each of Dr. He and Dr. Mak will be compensated
consistent with the current compensation program for non-employee directors and did not enter into any compensation arrangements
at the time of their election.
A copy of the Company's press release
issued on February 6, 2012 regarding the election of Dr. He and Dr. Mak is filed as Exhibit 99.1 to this Form 8-K and is hereby
incorporated herein by reference.
Item 8.01. Other Information.
In connection with the Transaction, Celgene
Corporation, the sole holder of the Company's outstanding Series A Convertible Preferred Stock ("Series A Preferred"),
agreed to vote in favor of the Transaction at the Company's 2012 stockholder meeting and, upon the approval of the Transaction
at such stockholder meeting, to (i) convert all outstanding shares of its Series A Preferred into common stock; (ii) waive all
accrued dividends on the Series A Preferred, and (iii) terminate all governance rights associated with the Series A Preferred.
A copy of the Company's press release
issued on February 6, 2012 regarding the consummation of the Transaction is filed as Exhibit 99.2 to this Form 8-K and is hereby
incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibits
99.1 	Press Release issued by dated February 6, 2012.
99.2	Press Release issued by dated February 6, 2012.
3
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ENTREMED, INC.
By:
/s/  Cynthia W. Hu
Name: Cynthia W. Hu
Title:   COO, General Counsel & Secretary
Date:
February 6, 2012
4
Exhibit Index
99.1 	Press Release issued by dated February 6, 2012.
99.2	Press Release issued by dated February 6, 2012.
5